Group 1: Economic Development and Innovation - Pudong has achieved significant breakthroughs in high-end industries, focusing on integrated circuits, biomedicine, and artificial intelligence, with a projected scale of 832.3 billion yuan for these industries by 2024, reflecting an average annual growth of 11.7% over the past three years [2] - The autonomous driving industry in Pudong has rapidly developed, supported by policies such as the issuance of the first batch of intelligent connected vehicle demonstration operation licenses in July 2023 [2] - Pudong has established a complete innovation chain for humanoid robots, fostering brands like Zhiyuan Robotics, and aims to create a technology-driven industrial ecosystem [3] Group 2: Policy and Regulatory Framework - Pudong has implemented the "One Industry, One License" reform, streamlining multiple permits into a single comprehensive license, which has been widely welcomed by businesses and is now applied in over 50 industries [6] - The region has made significant progress in institutional innovation, with 80 tasks from the overall plan for high-level institutional opening having been largely implemented, including the first cross-border digital RMB transaction for crude oil [7] - Pudong is actively exploring international rule alignment in investment access, trade facilitation, and cross-border data flow, aiming to enhance its global competitiveness [13] Group 3: Support for Enterprises - The establishment of the "Going Global Center" in Pudong provides comprehensive services for enterprises looking to expand internationally, with over 270 global sites and a network covering key regions [11] - The center offers a full range of services including market research, business matching, and cross-border operational support, addressing challenges faced by high-tech companies in their international ventures [12] - Pudong is also facilitating the entry of foreign enterprises into China, leveraging its innovative institutional advantages to provide a low-cost and convenient pathway for overseas SMEs [12]

Core Viewpoint - Shanghai Pudong New Area has achieved significant milestones in its development over the past 30 years, particularly since being designated as a leading area for socialist modernization in 2020, with a focus on high-quality development and higher-level openness [1] Group 1: Technological Innovation - Pudong has focused on cutting-edge technology innovation, achieving important breakthroughs in key industries such as integrated circuits, biomedicine, and artificial intelligence, with a projected scale of 832.3 billion yuan for these industries by 2024, reflecting an average annual growth of 11.7% over the past three years [2] - The autonomous driving industry in Pudong has rapidly developed, supported by policies such as the issuance of the first batch of intelligent connected vehicle demonstration operation licenses in July 2023 [2] - Pudong has established a complete innovation chain for humanoid robots, fostering brands like Zhiyuan Robotics, and aims to create a technology-driven industrial ecosystem [3] Group 2: Biomedicine Sector - Pudong has implemented several policies to support the high-quality development of the biomedicine industry, resulting in the emergence of representative medical enterprises and continuous innovation in the sector [4] - Companies like Hutchison China MediTech have thrived in Pudong, emphasizing the region's supportive environment for growth and innovation [5] Group 3: Reform and Regulation - Since the 14th Five-Year Plan, Pudong has made significant progress in implementing national strategies, achieving a 93% overall implementation rate for key tasks [6] - The "One Industry, One License" reform has streamlined the licensing process for businesses, enhancing operational efficiency and gaining widespread approval from enterprises [6] - Pudong has been a pioneer in institutional innovation, with 80 tasks from the overall plan for high-level institutional opening having been largely implemented, including significant advancements in trade facilitation and cross-border data flow [7] Group 4: Government Services and Support - Pudong has enhanced its administrative services through AI-driven systems, improving efficiency and accessibility for businesses [8] - The establishment of the "Going Global" comprehensive service center has provided extensive support for enterprises seeking to expand internationally, with over 270 global sites established [11] - The center offers a full range of services, including market research, business matching, and risk management, facilitating smoother international operations for local companies [12] Group 5: Future Outlook - Pudong aims to become a national model for higher-level reform and opening up, focusing on attracting international talent and fostering world-class multinational enterprises [13] - By 2024, Pudong's GDP is expected to reach 1.78 trillion yuan, representing a 34% increase from 2020, with a projected 6% year-on-year growth in the first three quarters of 2025 [13]

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report highlights a concentrated trend of domestic innovative drug collaborations and transactions as the year ends, with expectations for value recovery in 2026 [1][4] - The overall market performance shows a decline, with the Hang Seng Index down 0.8% and the Hang Seng Healthcare Index down 4.3% during the week [4][7] - The report emphasizes the importance of stock selection logic returning to fundamentals and valuations, focusing on stocks that are currently undervalued with expected fundamental improvements [4] Valuation Summary - The report provides a detailed valuation overview of various companies, indicating target prices and earnings per share estimates for FY25E and FY26E, along with their respective price-to-earnings ratios [3] - Notable companies with "Buy" ratings include AstraZeneca, BeiGene, and Hansoh Pharmaceutical, with target prices significantly above current trading prices [3] Market Trends - The report notes a slight decrease in domestic institutional holdings through the Hong Kong Stock Connect, while foreign holdings remain stable [33] - The report identifies a trend of increasing positions in leading innovative pharmaceutical companies by domestic investors, particularly in companies like Heng Rui Medicine and Rongchang Bio [36] Investment Insights - The report mentions several significant business development (BD) transactions exceeding $1 billion, indicating a robust pipeline for innovative drugs [4][5] - It recommends focusing on specific segments such as innovative drugs and CXO companies that are expected to benefit from downstream recovery and high market demand [4]

Market Overview - The Hang Seng Index has short-term support at the 25,000 point level, with expectations of two interest rate cuts in 2026 following the Federal Reserve's recent 0.25% rate cut, which aligns with market predictions [2][4] - The Chinese economy is projected to grow around 5% this year, with a total economic volume expected to reach approximately 140 trillion yuan [9] - The Hong Kong stock market has seen significant gains this year, leading to profit-taking incentives as trading volume decreases [2][7] Company News - Alibaba (9988) launched the Wanxiang 2.6 series model, introducing the first role-playing feature in the domestic market [11] - Baidu (9888) reported that its no-code application platform, Miaoda, has generated over 500,000 business applications, creating value exceeding 5 billion yuan [11] - The Hong Kong Stock Exchange (0388) is currently processing over 300 listing applications, reflecting strong market interest [11] - Tencent's major shareholder, Prosus, is accelerating its share buyback program, utilizing funds from the sale of assets outside of Tencent [11] - AMD's CEO visited Lenovo Group to explore collaboration opportunities in advanced technologies [11] Sector Focus - The AI sector is gaining traction with the launch of AI glasses and smartphones, benefiting related industry stocks [8] - The biopharmaceutical sector is expected to thrive due to rising flu cases and favorable financing conditions following interest rate cuts [8] - The insurance sector in the Asia-Pacific region is projected to maintain a neutral outlook, supported by resilient performance and strong solvency [9]

Core Viewpoint - Hutchison China MediTech Limited (HCM) has initiated global Phase I clinical development for HMPL-A251, a first-in-class PI3K/PIKK-HER2 antibody-drug conjugate (ATTC) designed to target HER2-expressing tumors [1][2]. Group 1: Clinical Development - The Phase I/IIa trial is an open-label, multicenter study aimed at evaluating the safety and efficacy of HMPL-A251 in adult patients with unresectable, HER2-expressing advanced or metastatic solid tumors [2]. - The study consists of two phases: the Phase I dose escalation phase and the Phase IIa dose expansion and optimization phase, focusing on determining the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) [2]. - Primary endpoints include safety, tolerability, and preliminary efficacy, while secondary endpoints encompass initial anti-tumor activity, pharmacokinetics, and immunogenicity of HMPL-A251 [2]. Group 2: Drug Characteristics - HMPL-A251 is the first candidate from HCM's new generation ATTC platform, utilizing a potent and selective PI3K/PIKK inhibitor as the payload [2]. - The drug is designed to precisely target HER2-expressing tumor cells, potentially overcoming systemic toxicity and narrow therapeutic windows associated with traditional PI3K/PIKK inhibitors [2]. - The strategy aims to enhance overall tolerability while achieving more effective and sustained pathway inhibition [2]. Group 3: Preclinical Data - Preclinical data for HMPL-A251 was presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targeted Therapy and Cancer [3]. - These data support the translational potential of the ATTC platform and the ongoing global clinical evaluation of HMPL-A251 [3]. - The combination of PI3K/PIKK inhibitors with linker-payload technology shows promise for developing a series of future ATTC candidates [3].

Core Insights - Hutchison China MediTech Limited (HCM) has announced the initiation of global Phase I clinical development for HMPL-A251, a first-in-class PI3K/PIKK-HER2 antibody-drug conjugate (ADC) [1][2] - The study aims to evaluate the safety and efficacy of HMPL-A251 in adult patients with unresectable, HER2-expressing advanced or metastatic solid tumors [1] Group 1: Clinical Development - HMPL-A251 is the first candidate from HCM's next-generation ADC platform to enter clinical development [2] - The clinical trial will be conducted in the United States and China, with the first patient dosed on December 16, 2025 [1] - The study consists of a Phase I dose-escalation stage and a Phase IIa dose-expansion and optimization stage, focusing on safety, tolerability, and preliminary efficacy [1] Group 2: Mechanism and Innovation - HMPL-A251 utilizes a highly selective and potent PI3K/PIKK inhibitor as the payload, coupled with a humanized anti-HER2 IgG1 antibody via a cleavable linker [1][2] - This innovative approach aims to target HER2-expressing tumor cells precisely, potentially overcoming systemic toxicity and narrow therapeutic windows associated with traditional PI3K/PIKK inhibitors [2] - Preclinical data supporting the potential of the ADC platform were presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targeted Therapy and Cancer [2]

Core Viewpoint - Hutchison China MediTech Limited (00013.HK) has announced the initiation of global Phase I clinical development for HMPL-A251, a first-in-class PI3K/PIKK-HER2 antibody-drug conjugate (ATTC) [1] Group 1 - HMPL-A251 is composed of a highly selective and potent PI3K/PIKK inhibitor as the payload and a humanized anti-HER2 IgG1 antibody linked by a cleavable linker [1] - The clinical study will be conducted in both the United States and China [1] - The first patient received the initial dose of treatment on December 16, 2025, in China [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概 不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） 和黃醫藥啓動ATTC候選藥物HMPL-A251用於治療實體瘤的全球臨床開發 — 新一代 ATTC 平台下候選藥物首次進入人體臨床試驗 ― ― 中國與全球同步臨床開發策略，加速推進研發進程 ― 和黃醫藥（中國）有限公司（簡稱「和黃醫藥」或 「HUTCHMED」）今日宣佈啟動HMPL-A251的全球I期臨床開發 項目。 HMPL-A251 是一款全球首創的PI3K/PIKK- HER2抗體靶向偶聯藥物（「ATTC」），由高選擇性、強效的 PI3K/PIKK抑制劑作為有效載荷（payload）和人源化抗HER2 IgG1抗體通過可裂解的連接子（linker）偶聯而成。 研究將於美國和中國開展。首名患者已於2025年12月16日於中國接受首次給藥治療。 這項首個人體試驗是一項 I/IIa 期、開放標簽、多 ...

Core Viewpoint - The inclusion of 19 drugs in the first version of the commercial health insurance innovation drug directory marks a significant step towards improving access and affordability of innovative drugs, particularly high-cost CAR-T therapies, while presenting challenges for insurance companies in product development and risk management [1][4][10]. Group 1: Policy and Implementation - The National Medical Security Work Conference emphasized the support for the development of commercial health insurance and the establishment of a multi-tiered medical security system, with a focus on the implementation of the commercial health insurance innovation drug directory by January 1, 2026 [1][2]. - The first version of the commercial health insurance innovation drug directory includes 19 drugs, focusing on high-cost and innovative treatments, including five CAR-T products and drugs for rare diseases [2][4]. Group 2: Challenges for Insurance Companies - Insurance companies face significant challenges in translating the drug directory into viable insurance products, including issues related to pricing, risk control, and compliance [4][5]. - Accurate pricing for insurance products relies on detailed data regarding potential patient populations, disease incidence, treatment cycles, and real-world efficacy, which are primarily held by pharmaceutical companies and hospitals [4][5]. Group 3: Risk Management and Compliance - The inclusion of Alzheimer's disease treatments raises concerns about adverse selection risks, as these drugs have high costs and long treatment durations, necessitating strict eligibility criteria for insurance coverage [5][6]. - Establishing transparent and compliant financial flows between insurance companies and pharmaceutical firms is crucial for effective collaboration [5][6]. Group 4: Data Sharing and Integration - The "医保+商保" one-stop clearing and settlement model aims to break down data silos, enhancing the efficiency of claims processing and improving patient experiences [6][8]. - Successful implementation of data sharing initiatives in regions like Shanghai and Beijing indicates potential for nationwide adoption, which could facilitate better integration of commercial health insurance with innovative drug offerings [8][10]. Group 5: Investment in Innovative Drugs - The policy encourages insurance funds to invest in the upstream of the pharmaceutical industry, positioning them as "patient capital" for innovative drug development [10][11]. - Major insurance companies are already investing in health industry funds, supporting numerous innovative drug companies and enhancing the overall funding environment for drug development [10][11]. Group 6: Future Outlook - Despite the potential for increased investment in innovative drugs, insurance companies remain cautious due to the high risks and costs associated with drug development, which may lead to a preference for established pharmaceutical firms over smaller, innovative companies [12].

Summary of the Conference Call on the Pharmaceutical Industry Industry Overview - **Industry**: Pharmaceutical Industry - **Rating**: Leading - **2026 Outlook**: Value recovery, upward trend continues, selective layout amidst differentiation [1] Core Insights and Arguments - **Industry Trends**: - The industry is expected to maintain a relatively fast growth rate despite tightening drug regulations and increasing challenges in new drug development in the U.S. [2] - The integration trend within the industry is just beginning, with leading players in high-growth segments showing strong long-term certainty [2] - **Private Hospitals**: - High-quality private hospital targets are recommended as cost control pressures ease and outdated capacities are eliminated, allowing for a return to faster growth [3] - Recommended stocks include Gushengtang and Haijia Medical, which are expected to rebound in the short term and have clear long-term expansion paths [3] - **Valuation Summary**: - A detailed table of various pharmaceutical companies with their stock codes, ratings, target prices, closing prices, earnings per share (EPS), price-to-earnings ratios (P/E), and other financial metrics is provided [4] Important but Overlooked Content - **Market Performance**: - The MSCI China Pharmaceutical Index increased by 62.0% year-to-date, outperforming the MSCI China Index by 31.8 percentage points [10] - The pharmaceutical sector has officially entered a rebound phase, with significant performance differentiation among sub-sectors [10] - **Policy Environment**: - The policy environment is improving, with the government supporting innovative drug development and introducing commercial insurance funds to supplement the medical insurance directory [11] - The latest round of medical insurance negotiations has successfully included 127 drugs outside the directory, indicating a shift towards a more balanced pricing strategy [11] - **Innovation and R&D**: - The industry is witnessing a positive cycle of R&D breakthroughs and global licensing, with many companies entering a "R&D investment - clinical breakthrough - global licensing" cycle [11] - As of September 2025, Chinese pharmaceutical companies have completed 103 overseas transactions, exceeding 77% of the total transaction amount for 2024 [11] - **Financial Performance**: - The overall revenue of the A-share pharmaceutical sector showed a marginal recovery in Q3 2025, with a 0.7% year-on-year increase, indicating strong operational resilience [17] - The sector's earnings growth expectations are improving, with leading companies showing rapid recovery in performance [11][20] - **Investment Opportunities**: - The report emphasizes two main investment lines: focusing on innovative companies with strong differentiation and product export potential, and capitalizing on the recovery of valuation multiples and earnings growth [32][34] - Specific recommendations include companies like Sanofi Pharmaceutical, Deqi Pharmaceutical, and Baiji Shenzhou, which have rich catalysts and are still undervalued [35] - **AI in Healthcare**: - The application of AI in healthcare is highlighted as a new theme for industry innovation, with significant market expansion potential [33] - **Future Outlook**: - The pharmaceutical industry is expected to maintain a stable upward trend in 2026, with a focus on fundamental performance and valuation [30] - The introduction of the commercial insurance innovative drug directory and ongoing policy reforms are anticipated to further enhance market sentiment and fundamental expectations [37]